FDA Peptide Reclassification 2026: What It Means for Providers FDA considers adding a dozen peptides to its bulk drug compounding list RAPS The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides